The textbook explanation for NSAID gut toxicity? Wrong. Two new studies show the gut microbiome, not prostaglandin suppression, drives GI injury. The microbiome can no longer be an afterthought in drug development. #microbiome# #pharma# #drugdiscovery#

Drug discovery is becoming a computational science. Richard Bonneau leads AI for drug discovery at @Genentech. Catch him bringing what's actually working to #FullyConnected26#. Sept 29–Oct 1, SF. Register here:

⚛️ Quantum computers could transform everything from drug discovery to logistics, but getting there won't be cheap. More on this week's Reuters Econ World podcast

NewLimit CEO @jacobkimmel predicts AI will bring drug discovery back to the phenotypic paradigm that dominated from the 1930s to 1970s: "A lot of the medicines that first came about in the 1930s through the 1970s, we actually didn't know the mechanism for. They were discovered empirically, meaning someone created a molecule, they put it in an animal, and they asked what happened." "This is how Paul Janssen, I believe he probably holds the record for inventing the most drugs ever in history. He would synthesize new compounds, put them in a series of rats, and ask what they might be feeling as a result of that drug." "What AI will bring us back to is more of that phenotypic paradigm where we can come up with compositions that have the effects we want, and maybe we don't understand them on day one. We can't explain it or draw out a diagram on a whiteboard of exactly what's happening." "But if it's effective and it's safe, that's all that's necessary for a medicine. It doesn't matter if we have a nice succinct story to tell about it." @newlimit

A 2025 #ScienceReview# looked at a different approach to drug discovery that may enable drugging of unconventional targets through stabilization of macromolecular complexes with molecules known as “LOCKTACs.” Learn more: #ScienceMagArchives#

A 2025 #ScienceReview# looked at a different approach to drug discovery that may enable drugging of unconventional targets through stabilization of macromolecular complexes with molecules known as “LOCKTACs.” Learn more: #ScienceMagArchives#

NOVA Conviction Update + Incentive Alignment We didn't choose drug discovery because it was an easy or fast problem to solve. We chose it because it's one of the hardest and most meaningful problems AI can tackle. Our ambition and track record reflects our commitment to long-term value creation. Since launching, NOVA has shipped 3 incentive mechanisms, established 3 relevant partnerships with other biotech companies outside of the Bittensor ecosystem, provided open-source access to optimized and fine-tuned SOTA models, run ongoing screening campaigns across multiple therapeutic modalities, and much more. That work has been funded by token sales and it will continue on multi-year timelines regardless of short-term price action. As the conviction mechanism rolls out across Bittensor, we want to be transparent about how we're approaching it by locking company tokens and aligning founder incentives with subnet growth. Company Wallet — 50% Locked Even before conviction, we've always balanced self-financing with token health. We locked 50% of our company tokens formalizing that commitment (and we’re one of the top subnets in % and TAO equivalent). From here, the owner's cut will be automatically locked so our conviction will only grow over time. The liquid 50% funds operations through token sales and OTC, and gives us flexibility to navigate price volatility. We will continue to minimize price impact and optimize for token health. Founder Incentive Alignment We're allocating 20% of what we earn split across the four founders as a direct incentive. Each founder has real skin in the game, individually motivated to grow NOVA. Based on the current wallet distribution, each founder's individual position will remain below the top 10 holders after tax. This distribution naturally decentralizes stake across the team. Our upside is tied directly to yours. Built for the Long Term We came to Bittensor to build infrastructure that accelerates drug discovery. The problems we're solving have the potential to reshape how medicine is made with multi-year timelines and billions in implications. Long term thinking is baked into everything we do. Long-term thinking is baked into everything we do. We remain focused on: • building valuable discovery systems • advancing therapeutic development • expanding partnerships • improving incentive mechanisms • and creating lasting value for the network Thank you to everyone helping us build. This is only the beginning.

We’re launching the Geodesic Grand Challenges. What are the hardest questions in drug discovery that, if solved, could change what’s possible over the next 5–10 years? We’re asking you to help define them. Selected questions will become official Geodesic Grand Challenges. Each selected contributor receives 10,000 Geodesic credits. Once the challenges are selected, we’ll open a call for solutions, with a $1 million prize for a verified solution to each challenge. The next breakthrough starts with the right question. Submit yours！